Colorectal cancer (CRC) is the third most common cancer diagnosed in both men and women in the U.S. and the third most common annual cause of death due to cancer. The U.S. Preventive Services Task Force recommends screening average-risk adults for colorectal cancer starting at age 50 and then regularly thereafter.
Current screening methods are time consuming and, in the case of colonoscopy, can be invasive. Meridian is enrolling adults age 60 to 84 years with no history of colorectal cancer for an investigational blood test intended for early detection of CRC.
- Must be age 60 to 84
- Must NOT have undergone a colonoscopy within the past 9 years
- Must NOT have completed Cologuard or Epi proColon testing within the previous 3 years
- Must NOT have a history of colorectal cancer
- Must NOT have a known diagnosis of inflammatory bowel disease
- May receive compensation for time and travel
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can also talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.
Meridian Clinical Research
1201 Seven Locks Road, Suite 111
Rockville, MD 20854
Submit your information
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services.
Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.